AXGN:NSD-AxoGen, Inc (USD)

COMMON STOCK | Medical Devices | NSD

Last Closing Price

USD 18.61

Change

-0.15 (-0.80)%

Market Cap

USD 0.76B

Volume

0.22M

Average Target Price

USD 18.88 (+1.42%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

AxoGen, Inc., together with its subsidiaries, provides surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and Avive Soft Tissue Membrane, a minimally processed human umbilical cord membrane that can be used as a resorbable soft tissue covering to separate tissues in the surgical bed. In addition, the company offers AxoTouch two point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. It provides its products to hospitals, surgery centers, and military hospitals plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons in the United States, Canada, the United Kingdom and other European countries, South Korea, and internationally. AxoGen, Inc. is headquartered in Alachua, Florida. Address: 13631 Progress Boulevard, Alachua, FL, United States, 32615

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-01-25 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
ALGN Align Technology, Inc

+5.39 (+1.01%)

USD42.11B 24.30 100.03
PODD Insulet Corporation

-1.39 (-0.48%)

USD19.14B 659.77 158.47
ABMD Abiomed, Inc

+0.42 (+0.12%)

USD15.72B 76.46 61.68
LVGO Livongo Health, Inc

N/A

USD14.20B N/A N/A
BRKR Bruker Corporation

-0.74 (-1.22%)

USD9.32B 60.12 28.92
TNDM Tandem Diabetes Care, Inc

+1.86 (+1.89%)

USD6.13B N/A N/A
IART Integra LifeSciences Holdings ..

+0.06 (+0.09%)

USD5.84B 105.00 26.55
SWAV ShockWave Medical, Inc

-2.03 (-1.56%)

USD4.45B N/A N/A
SDC SmileDirectClub, Inc

+2.30 (+20.80%)

USD4.27B N/A N/A
WMGI Wright Medical Group N.V

N/A

USD3.90B N/A 50.67

ETFs Containing AXGN

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Medical Devices)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 3.97% 19% F 40% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 3.97% 19% F 40% F
Trailing 12 Months  
Capital Gain 49.72% 69% D+ 72% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 49.72% 69% D+ 72% C-
Trailing 5 Years  
Capital Gain 290.97% 86% B 85% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 290.97% 86% B 85% B
Average Annual (5 Year Horizon)  
Capital Gain 51.06% 88% B+ 90% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 51.06% 88% B+ 90% A-
Risk Return Profile  
Volatility (Standard Deviation) 104.77% 14% F 10% F
Risk Adjusted Return 48.73% 74% C 70% C-
Market Capitalization 0.76B 66% D 60% D-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Medical Devices)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 6.26 49% F 28% F
Price / Cash Flow Ratio -38.35 85% B 88% B+
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -19.30% 64% D 36% F
Return on Invested Capital -22.23% 58% F 28% F
Return on Assets -8.97% 62% D- 29% F
Debt to Equity Ratio 1.21% 84% B 89% B+
Technical Ratios  
Short Ratio 5.11 36% F 24% F
Short Percent 3.26% 63% D 50% F
Beta 0.70 72% C- 79% C+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low debt

The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.